Overview

A Study to Evaluate the Effects of Asoprisnil(J867) in Women With Uterine Fibroids Who Are Scheduled for a Hysterectomy

Status:
Completed
Trial end date:
2005-05-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the effects of 10 mg and 25 mg doses of asoprisnil, compared to placebo, taken daily for 12 weeks, on uterine blood flow and the morphology of the endometrium and uterine fibroids.
Phase:
Phase 2
Details
Lead Sponsor:
Abbott